Comparison of Prohance® With Gadovist®/Gadavist™ in Magnetic Resonance Imaging (MRI) of the Brain (TRUTH)
This study is currently recruiting participants.
Verified February 2013 by Bracco Diagnostics, Inc
Sponsor:
Bracco Diagnostics, Inc
Information provided by (Responsible Party):
Bracco Diagnostics, Inc
ClinicalTrials.gov Identifier:
NCT01613417
First received: June 4, 2012
Last updated: February 5, 2013
Last verified: February 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study aims at a direct comparison between PROHANCE (0.1 mmol/kg) and a validated comparator GADOVIST/GADAVIST (0.1 mmol/kg) in a crossover intra-individual design in subjects with brain tumors to confirm the identical overall technical and diagnostic performance of the two MR contrast agents.
| Condition | Intervention | Phase |
|---|---|---|
|
Brain Disease |
Drug: Gadoteridol Drug: gadobutrol |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Crossover Assignment Masking: Double Blind (Subject, Investigator, Outcomes Assessor) Primary Purpose: Diagnostic |
| Official Title: | Phase IV, Double-blind, Multi-center, Randomized, Crossover Study to Compare 0.1 mmol/kg of Prohance® With 0.1 mmol/kg of Gadovist®/Gadavist™ in Magnetic Resonance Imaging (MRI) of the Brain (TRUTH) |
Resource links provided by NLM:
Further study details as provided by Bracco Diagnostics, Inc:
Primary Outcome Measures:
- Non-inferiority of each exam based on pre-dose and post dose images [ Time Frame: Up to 14 days ] [ Designated as safety issue: No ]To show non-inferiority of a 0.1 mmol/kg dose of PROHANCE as compared to 0.1 mmol/kg dose of GADOVIST/GADAVIST, in terms of the by-subject global diagnostic preference between exams (i.e., based on predose + postdose image sets).
| Estimated Enrollment: | 206 |
| Study Start Date: | August 2012 |
| Estimated Study Completion Date: | December 2013 |
| Estimated Primary Completion Date: | December 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: MRI with ProHance |
Drug: Gadoteridol
ProHance 0.1 mmol/kg
|
| Active Comparator: MRI with Gadovist/Gadavist |
Drug: gadobutrol
Gadovist/Gadavist 0.1 mmol/kg
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Are scheduled to undergo MRI
- Are willing to undergo two MRI procedures within 14 days
- Have confirmed or are highly suspected of brain disease likely to enhance as determined by the following:
- Clinical/neurological symptomatology;
- Diagnostic testing, such as CT or previous MRI examinations; or
- Have had previous brain surgery and are to be evaluated for recurrence.
Exclusion Criteria:
- Are pregnant or lactating females. Exclude the possibility of pregnancy:
- by testing on site at the institution within 24 hours prior to the start of each investigational product administration; or
- by history (i.e., tubal ligation or hysterectomy); or
- post menopausal with a minimum of 1 year without menses
- Have any known allergy to one or more of the ingredients in the investigational products, or have a history of hypersensitivity to any metals
- Have congestive heart failure (class IV according to the classification of the New York Heart Association; see Appendix A)
- Have suffered a stroke within a year
- Have received or are scheduled to receive any other contrast medium in the 24 hours preceding through the 24 hours following Exam 1, and in the 24 hours preceding through the 24 hours following Exam 2
- Have received or are scheduled to receive an investigational compound and/or medical device within 30 days before admission into the present study, through the 24 hours post-administration of the second investigational product.
- Have moderate-to-severe renal impairment, defined as a GFR/eGFR < 45 mL/min.
- Have been previously entered into this study
- Have received or are scheduled for one of the following:
- Surgery within three weeks prior to the first examination or between the two examinations
- Initiation of steroid therapy between the two examinations
- Radiosurgery between the two examinations
- Have any contraindications to MRI such as a pace-maker, magnetic material (i.e., surgical clips) or any other conditions that would preclude proximity to a strong magnetic field.
- Are suffering from severe claustrophobia
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01613417
Contacts
| Contact: Gianpaolo Pirovano, MD | 609-514-2226 | gianpaolo.pirovano@diag.bracco.com |
| Contact: Tara Rogers | 609-514-2577 | tara.rogers@diag.bracco.com |
Locations
| United States, New Jersey | |
| Holy Name Medical Center | Recruiting |
| Teaneck, New Jersey, United States | |
| Contact: Tara Rogers 609-514-2577 tara.rogers@diag.bracco.com | |
Sponsors and Collaborators
Bracco Diagnostics, Inc
Investigators
| Study Director: | Gianpaolo Pirovano, MD | Bracco Diagnostics, Inc |
More Information
No publications provided
| Responsible Party: | Bracco Diagnostics, Inc |
| ClinicalTrials.gov Identifier: | NCT01613417 History of Changes |
| Other Study ID Numbers: | PH-107 |
| Study First Received: | June 4, 2012 |
| Last Updated: | February 5, 2013 |
| Health Authority: | United States: Institutional Review Board Czech Republic: Ethics Committee Poland: Ethics Committee |
Keywords provided by Bracco Diagnostics, Inc:
|
Have confirmed or are highly suspected of brain disease |
Additional relevant MeSH terms:
|
Brain Diseases Central Nervous System Diseases Nervous System Diseases |
ClinicalTrials.gov processed this record on June 17, 2013